Piper Sandler analyst Allison Bratzel raised the firm’s price target on Travere Therapeutics to $11 from $10 on the lapse of a partial discounting period, while keeping a Neutral rating on the shares. The firm notes Travere pre-announced a Q4 2023 Filspari beat earlier this month, and Q4 2023 product sales of $40M, which it is incorporating into its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TVTX:
- Travere Therapeutics announces anticipated 2024 milestones
- Travere Therapeutics sees 2023 net product sales from cont. ops. $40M
- Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Travere Therapeutics price target raised by $2 at H.C. Wainwright, here’s why
- Travere Therapeutics price target raised to $20 from $18 at H.C. Wainwright